Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes.

To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in platinum-resistance relapsed Ovarian cancer patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xing Xie
• Treatments: Arsenic Trioxide; Olaparib

Criteria

Inclusion Criteria:

• 18-70years old;

• High grade (serous or endometrioid) epithelial ovarian cancers, fallopian tube or primary peritoneal carcinoma;

• Recurrent disease within 6 months of the last receipt of platinum-based chemotherapy;

• Measurable disease as per RECIST 1.1

• ECOG 0-2;

• Life expectancy ≥12 weeks;

• Confirmation of BRCA1/2 mutation and homologous recombination status ;

• PARPi naive;

• LVEF ≥ 50%;

• Bone Marrow Function: ANC：≥1.5×109/L； PLT：≥100×109/L；Hb: ≥90g/L;

• Liver and renal function:Serum creatinine ≤ normal upper limit (ULN) 1.5times; aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ULN 2.5times, or times, or ≤ ULN 2.5times if Gilbert's syndrome are present;

• The childbearing age subjects must agree to take effective contraceptive measures during the trial; the serum or urine pregnancy test must be negative, non-lactating;

• Signed the informed consent

Exclusion Criteria:

• Patients who had previously received >20% bone marrow radiotherapy in 1 week;

• Other malignant tumors have been found in the past 5 years,except for cured cervical carcinoma in situ, non melanoma of the skin;

• Uncontrolled systemic infection requiring anti-infective treatment;

• Allergies to the Fuzuloparib or Arsenic Trioxide or their excipients or intolerant patients;

• Subjects with ≥2 grade peripheral neuropathy according to CTCAE V 4.03;

• Researchers think it is not suitable for enrolling.